Search

Displaying results 1941 - 1950 of 8696 in total
  1. Drug

    Brexpiprazole

    go.drugbank.com/drugs/DB09128
    ApprovedInvestigational

    Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor … Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM).

    Categories: Antidepressive Agents Indicated for Depression, Cytochrome P-450 Substrates
  2. Drug

    Isoflavone

    go.drugbank.com/drugs/DB12007
    ApprovedInvestigationalWithdrawn

    The main soy isoflavones are mostly present in glycosylated forms and include [DB01645], [DB13182], and glycitein, which accounts for approximately 50%, 40%, and 10%, respectively, of the total soybean … The clinical benefits of soy proteins have been studied and demonstrated for many years, with some evidence of soy products associated with a reduced incidences of coronary heart disease, atherosclerosis

  3. Drug

    Quinethazone

    go.drugbank.com/drugs/DB01325
    Approved

    Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.

  4. Drug

    CM4620

    go.drugbank.com/drugs/DB16466
    Investigational

    CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    [A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. … Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  6. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [L24429] On May 4, 2023, it was approved by Health Canada.[L46327] … [L24474] It is an agonist of the melanocortin 4 receptor.

    Categories: Melanocortin 4 Receptor Agonist, Melanocortin 4 Receptor Agonists
  7. Drug

    Hexetidine

    go.drugbank.com/drugs/DB08958
    ApprovedWithdrawn

    It is used as a 0.1% mouthwash for local infections and oral hygiene.

    Mixtures: Isozid - H farblos - alkoholische Lösung zur Hautdesinfektion, Isozid - H gefärbt - alkoholische Lösung zur HautdesinfektionCategories: Antiinfectives and Antiseptics for Local Oral Treatment
  8. Drug

    Pentoxyverine

    go.drugbank.com/drugs/DB11186
    ApprovedWithdrawn

    It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists [A32160].

    Mixtures: Corzall PE
  9. Drug

    Mezlocillin

    go.drugbank.com/drugs/DB00948
    Approved

    It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  10. Target

    Endothelin receptor type B

    go.drugbank.com/bio_entities/BE0000043
    TargetHumans

    Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system

    Polypeptides: Endothelin receptor type BSynonyms: Endothelin receptor non-selective type